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PHeart Failure
elationship of Serum Digoxin
oncentration to Mortality and Morbidity
n Women in the Digitalis Investigation Group Trial
Retrospective Analysis
irkwood F. Adams, JR, MD, FACC,* J. Herbert Patterson, PHARMD,† Wendy A. Gattis, PHARMD,§
hristopher M. O’Connor, MD, FACC,§ Craig R. Lee, PHARMD,† Todd A. Schwartz, DRPH,‡
ihai Gheorghiade, MD, FACC
hapel Hill and Durham, North Carolina; and Chicago, Illinois
OBJECTIVES The purpose of this study was to investigate the relationship of serum digoxin concentration
(SDC) and outcomes in women with heart failure (HF).
BACKGROUND Controversy continues concerning the clinical utility of digoxin in women with HF.
METHODS Our analysis was retrospective with data from the Digitalis Investigation Group (DIG) trial.
The principal study analysis reviewed 4,944 patients with HF due to systolic dysfunction who
survived for at least 4 weeks (all 3,366 patients randomized to placebo and the 1,578 of 3,372
patients randomized to digoxin who had serum concentration measured 6 to 30 h [inclusive]
after the last dose of study drug at 4 weeks).
RESULTS Continuous multivariable analysis demonstrated a significant linear relationship between
SDC and mortality in women (p  0.008) and men (p  0.002, p  0.766 for gender
interaction). Averaging hazard ratios (HRs) across serum concentrations from 0.5 to 0.9
ng/ml in women produced a HR for death of 0.8 (95% confidence interval [CI] 0.62 to 1.13,
p  0.245) and for death or hospital stay for worsening HF of 0.73 (95% CI 0.58 to 0.93,
p  0.011). In contrast, SDCs from 1.2 to 2.0 ng/ml were associated with a HR for death
for women of 1.33 (95% CI 1.001 to 1.76, p  0.049).
CONCLUSIONS Retrospective analysis of data from the DIG trial indicates a beneficial effect of digoxin on
morbidity and no excess mortality in women at serum concentrations from 0.5 to 0.9 ng/ml,
whereas serum concentrations 1.2 ng/ml seem harmful. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.091497–504) © 2005 by the American College of Cardiology Foundation
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cigitalis glycosides have been used in the treatment of
eart failure (HF) for over two centuries and are still one
f the most common treatments prescribed for this
See page 505
ondition (1–3); however, the proper role of these drugs
n the contemporary management of HF in women remains
ontroversial. Recent analysis of all patients with reduced
jection fraction in the Digitalis Investigation Group (DIG)
From the *Departments of Medicine and Radiology, School of Medicine, †School
f Pharmacy, and the ‡Department of Biostatistics, School of Public Health,
niversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina; §Depart-
ent of Medicine, Duke Clinical Research Institute, Duke University, Durham,
orth Carolina; and the Department of Medicine, Northwestern University Medical
chool, Chicago, Illinois. Drs. Adams, Patterson, O’Connor, Gattis, and Gheo-
ghiade have or have had consulting, research relationships, and speaker bureau
upport from GlaxoSmithKline related to carvedilol but not digoxin. The DIG is
onducted and supported by the National Heart, Lung, and Blood Institute (NHLBI)
n collaboration with the DIG Study Investigators. This manuscript was not prepared
n collaboration with investigators of the DIG Study and does not necessarily reflect
he opinions or views of the DIG Study or the NHLBI. The authors would like to
edicate this manuscript to the late Dr. Thomas W. Smith, whose sense of
cholarship, high ideals, good nature, and untiring investigative efforts related to the
se of digitalis in patients with heart failure inspired this work.m
Manuscript received November 12, 2004; revised manuscript received February 8,
005, accepted February 14, 2005.rial suggested that digoxin might have limited benefits
n morbidity and might increase mortality in women (4).
urther review of this trial strongly suggested the effect of
igoxin on mortality in men with reduced ejection
raction was dependent upon serum concentration.
igher, but not lower, serum concentrations were asso-
iated with increased risk (5). If a similar relationship
xists in both genders, consideration of serum concentra-
ion would be necessary to define the effect of digoxin on
ortality in women. Adjusting for concentration might
ave greater impact in women, because they had higher
igoxin concentrations, compared with men, early in the
IG trial (6). Understanding whether digoxin is harmful
n women has substantial clinical importance, given that
0% of patients with HF are female and low-cost
edications are needed to ease the economic burden of
his syndrome.
To address this issue, we retrospectively analyzed data
rom the DIG trial with continuous multivariable analysis to
etermine if the relationship between serum concentration
nd mortality differed between women and men and
hether there was any evidence that digoxin, at low serum
oncentrations, increased mortality or failed to have a
orbidity benefit in women (7).
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tudy design. The DIG trial dataset was obtained from the
ational Heart, Lung, and Blood Institute under the
imited Access Dataset Procedure and its use was approved
y the University of North Carolina School of Medicine
iomedical Institutional Review Board. The design, patient
opulation, and conduct of the main trial in this study have
een well documented (7). The initial dose of study drug
as determined by an algorithm that took into account the
atient’s age, gender, weight, and renal function (8). The
nvestigator could modify the digoxin dose as necessary on
he basis of other factors, including co-administration of
rugs known to alter digoxin pharmacokinetics. Blinded
erum digoxin concentrations (SDCs) were determined in
n arbitrary subset of patients at their week four study visit
y radioimmunoassay (lower limit of detection 0.5 ng/ml) in
core laboratory (SmithKline BioScience, Norristown,
ennsylvania).
Abbreviations and Acronyms
CI  confidence interval
DIG  Digitalis Investigation Group
HF  heart failure
HR  hazard ratio
SDC  serum digoxin concentrationigure 1. Diagram that shows the relationship between the original study pop
nalyzed in the present study. LVEF  left ventricular ejection fraction.tudy population. A total of 6,738 of the 6,800 patients
nrolled in the main trial survived for at least 4 weeks of
ollow-up. Data were reviewed in 5,209 patients within this
roup, including all 3,366 patients randomized to placebo
nd all 1,843 patients randomized to digoxin who had a
erum concentration obtained at their four-week visit. The
DC was measured between 6 and 30 h (inclusive) after the
ast dose of study drug in 1,578 of these 1,843 patients and
hey, along with the 3,366 placebo patients, comprised the
rincipal patient group for analysis in this study (N 
,944). The SDCs were detectable in 1,451 of these 1,578
atients (1,133 men and 318 women), and a total of 1,416
atients (1,110 men and 306 women) had SDCs 0.5 to
.0 ng/ml (Fig. 1).
tatistical analysis. Multivariable Cox proportional haz-
rds regression modeling was performed to determine ad-
usted hazard ratios (HRs) for digoxin versus placebo for
arious study end points. In analyses involving SDC, de-
ectable serum concentrations (0.5 ng/ml) were treated as
linear continuous variable. The linear relationship between
oncentration and outcome was allowed to vary by gender.
atients randomized to digoxin who had undetectable
erum concentrations (0.5 ng/ml) were included as a
eparate group. Interactions for gender with SDC and the
ignificant covariates for mortality were tested. Additional
odeling of the relationship of serum concentration to
utcome was performed in women and men separately. To
ssess linearity of the relationship with SDC, a backwardulation in the Digoxin Investigation Group (DIG) trial and the patients
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August 2, 2005:497–504 Efficacy of Digoxin in Womenelection of polynomial terms through the fourth order was
onducted, and piecewise linear models were fitted with
ifferent slopes for lower (0.5 to 0.9 ng/ml) and higher
1.0 ng/ml) SDCs.
The modeling assessed the relationship between SDC at
he four-week visit and either time to all-cause mortality,
ime to the combined end point of all-cause mortality or
rst hospital stay due to worsening HF, or first hospital stay
ue to worsening HF alone (9). The following variables, in
ddition to treatment assignment, were considered as po-
ential covariates for the study end points of interest in a
ackward selection approach: digoxin use at baseline, race,
ge, gender, etiology (ischemic vs. nonischemic), body mass
ndex, systolic and diastolic blood pressures, heart rate,
esting left ventricular ejection fraction, cardiothoracic ratio,
rior myocardial infarction status, current angina pectoris
tatus, history of hypertension, history of diabetes, duration
f HF, New York Heart Association functional class,
iuretic use at baseline, nitrate use at baseline, vasodilator
se at baseline, reported symptoms score or clinical HF
core, and serum creatinine or estimated glomerular filtra-
ion rate. The clinical HF score was determined from
atient symptoms, signs, and chest X-ray results collected at
heir baseline visit. Data on serum creatinine were captured
rom the week four visit or the baseline visit if not available
t week four. Estimated glomerular filtration rate, expressed
s ml/min/1.73 m2 (10), was calculated from serum creati-
ine data with a modification of the prediction formula
erived from the Modification of Diet in Renal Disease
tudy (with all non-Caucasian patients considered as Afri-
an Americans).
For descriptive and clinical purposes, HRs for ranges of
DC compared with placebo were calculated from the
odels by averaging HRs across the serum concentrations
n a given range; ranges of interest included 0.5 to 0.9
g/ml, on the basis of findings from the Prospective
andomized Study of Ventricular Function and Efficacy of
igoxin (PROVED) and Randomized Assessment of
igoxin and Inhibitors of Angiotensin-Converting Enzyme
RADIANCE) data, and 1.2 to 2.0 ng/ml, representing
erum concentrations of possible harm in men (5,11).
djusted survival curves were also generated with categories
f serum concentration with the same covariates as for the
ontinuous analysis.
Baseline characteristics were compared between women
ith and without SDCs measured between 6 and 30 h after
he last dose of study drug and in women across categorical
DC ranges (0.5 to 0.9 ng/ml and 1.2 to 2.0 ng/ml) and
lacebo with chi-square statistics for categorical variables
nd one-way analysis of variance for continuous variables.
or any baseline covariate with an imbalance across the three
roups, significant pairwise comparisons were identified with a
onferroni adjustment. Mean SDC and the time since the
ample was drawn were compared between men and women
y Student t test. Data are shown as mean  SD. TESULTS
aseline characteristics. Overall, the clinical characteris-
ics of the women randomized to placebo and those in the
ow serum concentration group (0.5 to 0.9 ng/ml) and the
igh serum concentration group (1.2 to 2.0 ng/ml) were
omparable (Table 1). Women with low serum concentra-
ions did have a higher estimated glomerular filtration rate
nd diastolic blood pressure than women with high serum
oncentrations (p  0.05 after Bonferroni adjustment), but
either group was significantly different from placebo.
omen with higher serum concentrations had greater HF
cores at baseline compared with those on placebo (p 0.05
fter Bonferroni adjustment), but not compared with those
n the low serum concentration group. The SDC was
ignificantly greater in women compared with men (1.05
0.45 ng/ml vs. 0.96  0.41 ng/ml, p  0.003) among
atients with measurable concentrations (0.5 ng/ml)
btained 6 to 30 h after dosing of study drug at week 4.
verall, the baseline characteristics of women with and
ithout SDC measurement were comparable (Table 2)
nd any differences found were accounted for in the
ultivariable modeling.
ontinuous modeling of SDC, gender, and mortality. In
ll patients with detectable serum concentrations (women
nd men considered together), a significant linear relation-
hip was observed between the adjusted relative risk of death
nd SDC (p  0.001). Curve fitting with higher order
odels (second, third, and fourth order) were all nonsignif-
cant (all p  0.119), and attempts to fit a piecewise linear
odel with a different slope at lower (0.5 to 0.9 ng/ml) and
t higher (1.0 ng/ml) concentrations was also nonsignif-
cant (p  0.956). The risk of mortality did not differ in the
27 patients with undetectable SDCs compared with pla-
ebo (adjusted HR of 1.01 with 95% confidence interval
CI] from 0.74 to 1.37, p  0.947).
A significant linear relationship was found between SDC
btained 6 to 30 h after last dose of study medication and
he risk of death relative to placebo in both women (p 
.0078) and men (p  0.001). Given this continuous
elationship, the effect of digoxin versus placebo on mortal-
ty in either gender is best assessed by viewing point
stimates for mortality across a range of serum concentra-
ions (Fig. 2). Although there was some separation in the
urves for serum concentrations above 1 ng/ml, the test for
nteraction with gender was not significant (p  0.766,
ested for equal intercepts and equal slopes), and there was
ide overlap of the CIs between women and men. No
ignificant interaction with gender was found when baseline
haracteristics that differed between women with and with-
ut SDC measurements were forced into the continuous,
ultivariable analysis (p  0.780).
The validity of the model was also confirmed by testing
or potential interactions between gender and each of the
ovariates in the final multivariable model for mortality.
his analysis determined that the only covariate whose
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Efficacy of Digoxin in Women August 2, 2005:497–504ssociation with mortality was influenced by gender was the
istory of diabetes (nominally significant with p  0.032);
owever, the nonsignificance of the interaction between
ender and the relationship of serum concentration to
ortality was unchanged when this term was included in
he modeling (p  0.763). Additional continuous multiva-
iable analysis with all available SDCs, regardless of the time
rom study drug administration, demonstrated a significant
inear relationship between serum concentration and mor-
ality similar to the primary analysis in both men (p 
.001) and women (p  0.001), and there was still no
ignificant interaction with gender (p  0.327). A signifi-
ant linear relationship was also found between SDC and
ortality when modeling was conducted in women alone
p  0.007).
Rs across ranges of SDC. The HRs derived from the
esults of the continuous modeling were averaged across
arious concentration ranges to demonstrate the clinical
mportance of the SDC-mortality relationship in both
omen and men (Tables 3, 4, and 5). There was a
uggestion of reduced mortality in men and no effect on
ortality in women at serum concentrations from 0.5 to 0.9
g/ml, whereas serum concentration 1.2 ng/ml seemed
able 1. Baseline Characteristics of Women in the Study Subgro
Characteristic Placebo SDC
757
ge (yrs) 65  12
ace (non-white) (%) 19
MI (kg/m2) 27  6.3
revious digoxin use (%) 45
revious MI (%) 53
urrent angina (%) 29
ypertension (%) 54
schemic etiology (%) 60
iabetes (%) 34
YHA functional class (%)
I 9
II 51
III 38
IV 2
CE inhibitor 94
iuretic 88
itrate 43
asodilator therapy 3.8
VEF (U) 30  9.0
uration of CHF (months) 27  32
BP (mm Hg) 128  21
BP (mm Hg) 75  12
eart rate (beats/min) 81  13
T ratio (%) 0.56  0.08
HF score (U) 12  5
GFR (ml/min/1.73 m2) 60  34
DC (ng/ml) NA
ime sample drawn (h) NA
DC groups based on samples obtained within 6 to 30 h after last dose of study dru
cross all three groups (see Results for pairwise comparison testing).
ACE angiotensin converting enzyme; BMI body mass index; CHF congest
lomerular filtration rate; LVEF  left ventricular ejection fraction; MI  myocardia
serum digoxin concentration.armful in both genders. Similar relationships were ob- derved in women when survival curves with these serum
oncentration ranges were compared with placebo (Fig. 3).
erum concentration, gender, and other end points. Con-
inuous multivariable modeling demonstrated a significant
inear relationship between SDC versus placebo and the risk
f the combined study end point (in women p  0.033, and
en p 0.011; Fig. 4). In contrast, modeling did not reveal
significant linear relationship between the risk of hospital
tay alone in women (p  0.297) or men (p  0.313),
lthough there were trends for a greater benefit on this end
oint at lower compared with higher serum concentration in
omen and men as well (Table 3). There was no significant
nteraction between gender and the risk of either of these
nd points (combined, p  0.679, and hospital stay alone, p
0.306). Averaging HRs across ranges of SDC revealed
ubstantial and similar reductions in the risk of the com-
ined study end point and the risk of hospital stay due to
orsening HF in both women and men at low serum
oncentrations, whereas less evidence of benefit was seen at
igher concentrations (Table 3).
ISCUSSION
ur retrospective analysis of patients from the DIG trial
According to SDC
–0.9 ng/ml) SDC (1.2–2.0 ng/ml) p Value
62 89
 12 65  12 0.509
19 15 0.547
 6.2 27  6.9 0.550
53 53 0.085
52 56 0.786
27 22 0.387
53 57 0.794
61 61 0.933
28 35 0.318
9 12
50 47
40 33
1 8 0.961
96 96 0.687
86 91 0.452
43 45 0.936
3.7 3.4 0.976
 9.0 29  9.4 0.309
 36 32  32 0.303
 22 125  20 0.188
 11 73  10 0.031
 12 80  12 0.586
 0.07 0.58  0.07 0.067
 5 14  6 0.012
 21 54  20 0.032
 0.13 1.44  0.22 0.001
 7.4 18  8.2 0.001
ults shown as mean  SD where appropriate. p values represent significance testing
art failure; CT cardiothoracic; DBP diastolic blood pressure; eGFR estimated
ction; NYHA  New York Heart Association; SBP  systolic blood pressure; SDCuped
(0.5
1
64
26
29
28
130
77
82
0.56
12
64
0.73
21
g. Res
ive heemonstrates that the clinical effects of digoxin in women,
a
t
v
d
s
T
v
s
s
a
h
c
w
n
s
n
I
w
t
n
a
o
e
m
c
g
w
6
r
r
H
n
o
F
o
a
e
a
501JACC Vol. 46, No. 3, 2005 Adams et al.
August 2, 2005:497–504 Efficacy of Digoxin in Womens in men, are significantly influenced by serum concentra-
ion, with divergent outcomes relative to placebo at low
ersus high concentrations. Specifically, there was no evi-
ence that digoxin increased mortality in women at low
erum concentrations by any of our analytical approaches.
he point estimate for the relative risk of death on digoxin
igure 2. Plot of the adjusted point estimates and 95% confidence intervals
f women and men for the hazard ratio for death on digoxin versus placebo
t various serum digoxin concentrations (ng/ml) with concentration mod-
Table 2. Comparison of Baseline Characteristi
Without a Measurement of SDC at Their We
Characteristic SDC Do
n 411
Age (yrs) 64  1
Race (non-white) (%) 19
Prior MI (%) 54
Current angina (%) 26
Hypertension (%) 55
Ischemic etiology (%) 63
Diabetes (%) 30
Previous digoxin use, yes (%) 52
NYHA functional class 2.3  0
BMI (kg/m2) 27  6
LVEF (U) 30  9
Duration of CHF (months) 31  3
SBP (mm Hg) 129  2
DBP (mm Hg) 75  1
Heart rate (beats/min) 81  1
CT ratio 0.56  0
CHF score (U) 12.4  5
eGFR (ml/min/1.73 m2) 61  2
ACE inhibitor 96
Diuretic 88
Nitrate 43
Vasodilator 3.2
Results shown as mean  SD where appropriate. *Present in
combined end point (Table 4); †not present in model of in
SDC yes and no.
Abbreviations as in Table 1.f
led as a continuous variable. The 95% confidence intervals for the women
re offset to allow better depiction of results.ersus placebo was below unity for women at detectable
erum concentrations 1 ng/ml. In addition, digoxin sub-
tantially reduced the risk of hospital stay for worsening HF
nd the risk of the combined end point of mortality and HF
ospital stay in women at low SDCs (0.5 to 0.9 ng/ml). In
ontrast, the risk for mortality was greater than placebo
hen serum concentrations were1.2 ng/ml, and there was
o reduction in the risk of the combined end point at higher
erum concentrations. Our study cannot define the mecha-
isms responsible for the adverse effect of higher SDCs.
ncreased SDC might have a pro-arrhythmic effect as seen
ith other positive inotropic agents even at the upper end of
he traditional therapeutic range. Additional studies are
eeded to better define the adverse effects of inotropic
gents on the failing human heart.
Our analysis concurs with the recent important findings
f Rathore et al. (5) concerning the relationship between the
fficacy of digoxin and serum concentration in men in the
ain DIG trial, with better outcomes at lower serum
oncentration and harm at higher concentrations. This
roup also reported a modest increase in mortality in
omen, but not men, in an analysis of all patients (N 
,800) in the main trial (4). Several explanations could
econcile our findings with those of Rathore et al. (4)
egarding the effects of digoxin on mortality in women with
F. First and most importantly, serum concentration sig-
ificantly influences the effect of digoxin on mortality, not
nly in men, but also in women. This critical confounding
Women Randomized to Digoxin With and
our Visit
SDC Not Done p Value
338
65  13 0.181
17 0.535
59 0.210
30 0.256
54 0.933
65 0.668
36 0.140
41 0.002*
2.4  0.7 0.077
27  6.4 0.634
31  8.6 0.075
24  34 0.009†
127  20 0.359
74  12 0.036†
82  13 0.497
0.57  0.08 0.500
12.4  5.2 0.895
57  20 0.012*
93 0.197
87 0.740
43 0.854
3.6 0.769
al model of independent risk factors for both mortality and
ent risk factors—forced to account for differences betweencs in
ek F
ne
2
.7
.4
.0
7
1
1
2
.08
.1
1
origin
dependactor could not be taken into account in an analysis of all
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Efficacy of Digoxin in Women August 2, 2005:497–504atients in the main trial. Measurement of serum concen-
ration in a subgroup of patients in the trial demonstrated
odestly but significantly higher SDCs in women, so that
ccounting for this confounding factor is even more impor-
ant. In addition, because serum concentrations are not
vailable in all patients in the main trial, the possibility of
ven greater gender differences in serum concentration
annot be excluded. Finally, the shape of the serum con-
entration outcome relationship in women suggests they
ight be more likely than men to have adverse effects at
igher serum concentrations (Fig. 2). Formal interaction
esting was negative, suggesting any difference in sensitivity
s likely small, although the combination of higher SDCs
nd the potential for greater likelihood of an adverse effect
f digoxin at serum concentrations 1.2 ng/ml could have
lso contributed to the findings of Rathore et al. (4) in the
ain trial population. Ultimately, the important therapeutic
able 3. Risk of Study End Points for Men and Women Derived
arious SDC Ranges
Outcome
SDC 0.5–0.9 ng/m
HR 95% CI
ortality
Men 0.80 0.70–0.92
Women 0.84 0.62–1.13
All patients 0.81 0.71–0.92
ombined end point
Men 0.70 0.63–0.79
Women 0.73 0.58–0.93
All patients 0.71 0.64–0.79
ospital stay for worsening
heart failure
Men 0.59 0.50–0.69
Women 0.70 0.53–0.94
All patients 0.61 0.53–0.70
values based on multivariable Cox proportional hazards modeling. Hazard ratio fo
CI  confidence interval; HR  hazard ratio; SDC  serum digoxin concentrat
able 4. Multivariable Analysis of SDC as an Independent Predi
Mortality End Point Adjusted Chi-Square
GFR (per 10 ml/min/1.73 m2) 18.8
revious digoxin use 23.0
ge (per 10 yrs) 36.1
ender (male) 44.0
YHA functional class 17.3
BP (per 5 mm Hg) 15.9
T ratio (per 0.05 U) 41.0
VEF (per 5 U) 65.2
iabetes 29.0
HF score 23.4
MI (per 5 kg/m2) 9.8
ace 0.8
itrate 13.0
iuretic 13.5
asodilator 6.2
reatment 20.6
DC 21.7
ndetectable SDC 0.01
he variable race was forced into the mortality analysis. p values based on Cox propo
oncentrations considered as a separate group.
Abbreviations as in Tables 1 and 3.ssue is not whether women and men differ to some degree
n their responsiveness to digoxin, but whether any differ-
nce has clinical consequences after taking into account the
nfluence of other important factors like serum concentra-
ion. Our analysis provides convincing evidence that the
enefits of low serum concentration outweigh any potential
ifferential response to digoxin by gender.
Our findings do not diminish the importance of investi-
ating the potential for gender differences in the benefits of
edications for HF. We and others have demonstrated
ignificant differences in baseline characteristics and survival
etween men and women with HF, suggesting the response
o medications for this condition might differ by gender
12–15). Enrollment of larger numbers of women in future
linical trials conducted in HF will help address this
mportant issue.
As with any retrospective, nonrandomized study, well
m the Continuous Multivariable Analysis Across
SDC 1.2–2.0 ng/ml
p Value HR 95% CI p Value
0.002 1.18 0.99–1.39 0.060
0.245 1.33 1.001–1.76 0.049
0.001 1.21 1.05–1.40 0.009
0.001 0.89 0.76–1.03 0.115
0.011 1.01 0.79–1.28 0.961
0.001 0.92 0.81–1.04 0.179
0.001 0.67 0.54–0.82 0.001
0.016 0.85 0.63–1.15 0.292
0.001 0.72 0.60–0.85 0.001
xin versus placebo.
of Mortality in Patients Randomized to Digoxin Versus Placebo
Hazard Ratio 95% CI p Value
0.94 0.91–0.97 0.001
1.27 1.15–1.39 0.001
1.19 1.12–1.26 0.001
1.53 1.35–1.74 0.001
1.17 1.09–1.27 0.001
0.97 0.96–0.99 0.001
1.12 1.08–1.16 0.001
0.89 0.86–0.91 0.001
1.34 1.20–1.48 0.001
1.02 1.01–1.03 0.001
0.92 0.87–0.97 0.002
0.94 0.81–1.08 0.370
1.20 1.09–1.32 0.001
1.35 1.15–1.58 0.001
1.36 1.07–1.73 0.013
NA NA 0.001
NA NA 0.001
1.01 0.74–1.37 0.947
l hazards model. SDC  0.5 ng/ml treated as a continuous variable with undetectedFro
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August 2, 2005:497–504 Efficacy of Digoxin in Womennown factors could have confounded our results. Our
odeling analysis did investigate serum concentration as
continuous variable with arbitrary cut points only used
o illustrate the clinical importance of the observed
elationship. Worse outcomes in patients with high
DCs could be related to underlying renal disease or
ore severe clinical HF; however, our results were
bserved after taking into account renal function and
arious characteristics indicative of HF severity. We also
igure 3. Plot of adjusted survival curves in placebo and various digoxin
erum concentration groups. Results from this categorical analysis demon-
trated that women with serum concentrations from 0.5 to 0.9 ng/ml had
imilar survival compared with those receiving placebo (hazard ratio 0.81,
ith 95% confidence interval from 0.58 to 1.14, p  0.229), whereas
omen with serum concentrations from 1.2 to 2.0 ng/ml seemed to have
able 5. Multivariable Analysis of SDC as an Independent Predi
o Digoxin Versus Placebo
Combined End Point Adjusted Chi-Square
GFR (per 10 ml/min/1.73 m2) 21.3
revious digoxin use 57.8
ge (per 10 yrs) 20.3
ender (male) 38.5
YHA functional class 26.5
BP (per 5 mm Hg) 26.5
T ratio (per 0.05 U) 54.8
VEF (per 5 U) 86.6
iabetes 53.1
HF score 43.4
MI (per 5 kg/m2) 3.0
ace 8.5
itrate 26.0
iuretic 29.9
asodilator 3.7
reatment 29.5
DC 11.1
ndetectable SDC 0.7
he variable race was forced into the mortality analysis. p values based on Cox prop
Abbreviations as in Tables 1 and 3.worse outcome (hazard ratio 1.11, with 95% confidence interval from
.78 to 1.60, p  0.557). SDC  serum digoxin concentration.
c
round women in the digoxin group with and without
erum concentration values to be reasonably comparable
t baseline (Table 2), and including any differences found
n the modeling did not alter our results. Because of the
harmacokinetics of digoxin, our primary analysis exam-
ned serum concentrations obtained within 6 to 30 h after
he last dose of study medication. Our results, however,
ere similar when all serum concentrations were included
igure 4. Plot of the adjusted point estimates and 95% confidence intervals
f women and men for the hazard ratio for the combined study end point
of all-cause mortality or first hospitalization due to worsening heart
ailure) on digoxin versus placebo at various serum digoxin concentrations
ng/ml) with concentration modeled as a continuous variable. The 95%
of Combined Mortality and Morbidity in Patients Randomized
HR 95% CI p Value
0.95 0.92–0.97 0.001
1.36 1.26–1.48 0.001
1.11 1.06–1.16 0.001
1.38 1.25–1.53 0.001
1.18 1.11–1.25 0.001
0.97 0.96–0.98 0.001
1.12 1.08–1.15 0.001
0.89 0.87–0.91 0.001
1.38 1.26–1.50 0.001
1.03 1.02–1.04 0.001
0.96 0.92–1.01 0.085
1.19 1.06–1.33 0.004
1.23 1.14–1.34 0.001
1.44 1.26–1.64 0.001
1.22 0.99–1.50 0.056
NA NA 0.001
NA NA 0.001
0.89 0.69–1.16 0.392
al hazards model.ctoronfidence intervals for the women are offset to allow better depiction of
esults.
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Efficacy of Digoxin in Women August 2, 2005:497–504n the analysis. Although our findings are based on a
odest number of women, their results were quite
onsistent with those of the men, especially with regard
o the strong relationship of clinical outcome to serum
oncentration and the beneficial effects of digoxin at low
erum concentrations on both the risk of the combined
tudy end point and the risk of hospital stay due to HF.
ome limitations concerning the generalizability of our
ndings should be mentioned. Only patients with symp-
omatic HF due to left ventricular systolic dysfunction
ere analyzed. Beta-blockers were not part of the usual
anagement of HF at the time of the DIG study.
hether digoxin would exert beneficial clinical effects on
utcomes at low serum concentrations in patients receiv-
ng beta blockers remains unknown.
Some might wonder why we should bother with digoxin,
iven recent advances in therapy for HF. But this question
gnores the public health perspective concerning this drug: a
amiliar, well tolerated, convenient, and inexpensive agent
hich, in our analysis, seems to have clinical benefit in both
omen and men at the proper serum concentration. Inte-
rating current biological and statistical understanding of
igoxin therapy with good clinical judgment suggests a
rudent strategy for the use of this drug in women with HF.
ecause the morbidity benefit seems greater and safety more
ikely at lower serum concentrations, administering low
oses (0.125 mg/day or less) to achieve serum concentra-
ions from 0.5 to 0.9 ng/ml is indicated. Dosing should
lways be individualized by considering age, body size, renal
unction, and concomitant interacting medications. Recog-
izing that women tend to have higher serum concentra-
ions than expected, the steady state concentration could
lso be monitored after approximately four weeks. Once
rough serum concentration is detectable but 1.0 ng/ml,
urther measurements are unnecessary unless renal function
eteriorates, an interacting drug is added, or digoxin toxicity
s suspected.
In conclusion, retrospective analysis of patients from
he DIG trial indicates that digoxin is an effective
reatment for HF in women with reduced ejection
ractions when this drug is used at low serum concentra-ions. A beneficial effect on morbidity and no excess
ortality was observed at serum concentrations from 0.5
o 0.9 ng/ml.
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